睿知中国医院研究地图
候选清单

正在招募肝细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06515314,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7

    入选标准第 6 条

    Another primary malignancy within 5 years (with some exceptions for completely-resected early-stage tumors)

    排除标准第 2 条

  3. Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T102 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis.

    入选标准第 11 条

    Toxicity of previous treatment has not been mitigated or ≤ Grade 1 at screening.

    排除标准第 1 条

  4. ECOG performance status ≤1.

    入选标准第 7 条

  5. Patients must have at least one measurable lesion defined by RECIST 1.1.

    入选标准第 9 条

  6. Known HIV or syphilis infection, and/or active hepatitis C virus infection.

    排除标准第 12 条

    HBV infect subjects with HBV-DNA≥2000IU/ml

    排除标准第 13 条

  7. Pregnant or lactating female, or those whose HCG test is positive before enrollment.

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06515314,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The patient must be willing to sign the informed consent form.
  2. Age ≥18 years and ≤75 years.
  3. HLA-A 02:03 allele positive
  4. Histologically-confirmed AFP positive hepatocellular carcinoma (HCC) or other solid tumor, No benefits from curative surgery or other local therapies are expected ,at least one prior line of systematic treatment at screening, judged by investigators.
  5. Fresh samples or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry (IHC)-stained AFP positive or serum AFP ≥400ng/ml.
  6. Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
  7. ECOG performance status ≤1.
  8. Estimated life expectancy ≥4 months.
  9. Patients must have at least one measurable lesion defined by RECIST 1.1.
  10. Patients with any organ dysfunction as defined below:
  11. Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T102 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis.

排除标准:Exclusion Criteria:

  1. Toxicity of previous treatment has not been mitigated or ≤ Grade 1 at screening.
  2. Another primary malignancy within 5 years (with some exceptions for completely-resected early-stage tumors)
  3. With severe cardiovascular disease or presence of clinically-relevant central nervous system (CNS) disorders in six months before screening.
  4. Systematic autoimmune disorders requiring long-term systematic immunosuppression
  5. Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions.
  6. Current presence of or previously with hepatic encephalopathy
  7. Organ transplanters and allogeneic cell transplanters.
  8. Have a history of gastrointestinal bleeding or a definite tendency to gastrointestinal bleeding within 3 months before screening
  9. Hereditary or acquired bleeding (e.g. coagulation dysfunction) or a tendency to clot
  10. Subject has active infection or unexplained fever during screening and prior to cell transfusion
  11. Have central nervous system metastasis with symptoms
  12. Known HIV or syphilis infection, and/or active hepatitis C virus infection.
  13. HBV infect subjects with HBV-DNA≥2000IU/ml
  14. Pregnant or lactating female, or those whose HCG test is positive before enrollment.
  15. Known uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure

引自 ClinicalTrials.gov, NCT06515314, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06515314,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06515314